Back to search

Article

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primates

2021-09-21

Abstract excerpt

<title>Abstract</title> <p>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies has raised concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated in preclinical models and in human clinical trials that our SARS-CoV-2 recombinant spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bbcecfe1-d0ea-507e-8649-2729097a1a9e
DOI
10.21203/rs.3.rs-871537/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesDOI 10.21203/rs.3.rs-871537/v1
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersSemantic proximity
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccinesSemantic proximity
COVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variantsSemantic proximity
Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1Semantic proximity
High efficacy of VLA2001 vaccine against SARS-CoV-2 infection in non-human primatesSemantic proximity
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2Semantic proximity
Dynamics of Temporal Immune Responses in Nonhuman Primates and Humans Immunized with COVID-19 VaccinesSemantic proximity
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsSemantic proximity
Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity
A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primatesSemantic proximity
Select a neighboring publication to make it the new centre.